ArticleIranian journal of basic medical sciences2026
A lipid metabolism-based gene signature defines diagnosis and molecular heterogeneity in diabetic nephropathy.
Article in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To identify lipid metabolism-related biomarkers of diabetic nephropathy (DN), develop and validate a diagnostic model, and further explore immune infiltration patterns and molecular subtypes of DN. Materials and Methods: Multiple public transcriptomic datasets were integrated to identify lipid metabolism-related biomarkers for DN using differential expression analysis, weighted gene co-expression network analysis, and machine learning. A diagnostic model was then constructed from these biomarkers, and its performance was evaluated using ROC curve and nomogram analyses, followed by validation in an independent cohort. In addition, immune cell infiltration was assessed with the CIBERSORT algorithm, and consensus clustering identified molecular subtypes of DN. Finally, the findings were validated in a model of type 2 diabetes. Results: A total of 28 lipid metabolism-related differentially expressed genes were identified, and five hub biomarkers (G0S2, PTGDS, CA2, CYP27B1, and HSD17B14) were screened and demonstrated favorable diagnostic performance in both training and validation cohorts. Functional enrichment analysis revealed that these genes were mainly involved in fatty acid metabolism and PPAR signaling pathways. Immune infiltration analysis revealed significant correlations between dysregulated lipid metabolism and immune cell infiltration in DN. Consensus clustering identified distinct molecular subtypes of DN with different lipid metabolic characteristics. Critically, bioinformatic predictions were validated in db/db mice, showing significantly elevated mRNA and protein levels of all five biomarkers in DN kidneys. Conclusion: Our findings reveal a validated lipid-metabolism-based diagnostic signature with potential for early detection, molecular stratification, and mechanistic investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.